Author:
Lorusso Domenica,García-Donas Jesús,Sehouli Jalid,Joly Florence
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Oncology
Reference62 articles.
1. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Ovarian cancer including fallopian tube cancer and primary peritoneal cancer (Version 3.2019).
https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf
. Accessed 3 Mar 2020.
2. Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24:vi24–vi32.
https://doi.org/10.1093/annonc/mdt333
.
3. Kemp Z, Ledermann JA. Update on first-line treatment of advanced ovarian carcinoma. Int J Womens Health. 2013;5:45–51.
https://doi.org/10.2147/IJWH.S30231
.
4. Wahlberg E, Karlberg T, Kouznetsova E, Markova N, Macchiarulo A, Thorsell AG, et al. Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors. Nat Biotechnol. 2012;30:283–8.
https://doi.org/10.1038/nbt.2121
.
5. Farmer H, McCabe N, Lord CJ, Tutt ANJ, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917–21.
https://doi.org/10.1038/nature03445
.
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献